

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Editorial**

- 409** Rheumatoid arthritis, bone and drugs: a dangerous interweave  
*S Minisola, J Pepe, C Cipriani*

**Viewpoint**

- 411** EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs  
*J WJ Bijlsma*

**Review**

- 413** Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis  
*W Hu, Y Chen, C Dou, S Dong*

**Rheumatoid arthritis**

- 423** Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study  
*S Abtahi, J H M Driessen, A M Burden, P C Souverein, J P van den Bergh, T P van Staa, A Boonen, F de Vries*

- 432** Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis  
*R M Fleischmann, R Blanco, S Hall, G T D Thomson, F E Van den Bosch, C Zerbini, L Bessette, J Enejosa, Y Li, Y Song, R DeMasi, I-H Song*

- 440** Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis  
*H Tsuchiya, M Ota, S Sumitomo, K Ishigaki, A Suzuki, T Sakata, Y Tsuchida, H Inui, J Hirose, Y Kochi, Y Kadono, K Shirahige, S Tanaka, K Yamamoto, K Fujio*

- 451** Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis  
*D Andreev, M Liu, K Kachler, M Llerins Perez, P Kirchner, J Kölle, A Gießl, S Rauber, R Song, O Aust, A Grüneboom, A Kleyer, J D Cañete, A Ekeci, A Ramming, S Finotto, G Schett, A Bozec*

**Spondyloarthritis**

- 469** Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?  
*X Baraliakos, A Richter, D Feldmann, A Ott, R Buelow, C O Schmidt, J Braun*

- 475** Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo  
*S Menegatti, V Guillemot, E Latis, H Yahia-Cherbal, D Mittermüller, V Rouilly, E Mascia, N Rosine, S Koturan, G A Millot, C Leloup, D Duffy, A Gleizes, S Hacein-Bey-Abina, Milieu Intérieur Consortium, J Sellam, F Berenbaum, C Miceli-Richard, M Dougados, E Bianchi, L Rogge*

**Osteoarthritis**

- 487** 10-Year natural course of early hip osteoarthritis in middle-aged persons with hip pain: a CHECK study  
*A C van Berkel, D Schiphof, J H Waarsing, J Runhaar, J M van Ochten, P J E Bindels, S M A Bierma-Zeinstra*

- 494** Constitutional morphological features and risk of hip osteoarthritis: a case-control study using standard radiographs  
*H Abdulrahim, Q Jiao, S Swain, K Sehat, A Sarmanova, K Muir, W Zhang, M Doherty*

- 502** Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative  
*M A Bowes, K Kacena, O A Alabas, A D Brett, B Dube, N Bodice, P G Conaghan*

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008  
J.M00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

**Pain**

**509** Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial



*P Dakin, A J Kivitz, J S Gimbel, N Skrepnik, S J DiMartino, C A Emeremni, H Gao, N Stahl, D M Weinreich, G D Yancopoulos, G P Geba*

**Epidemiology**

**518** Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries

*C DeJaco, A Alunno, J WJ Bijlsma, A Boonen, B Combe, A Finckh, P M Machado, I Padjen, F Sivera, T A Stamm, F Buttgerit*

**527** Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients



*FAFR/SFR/SNFM/ISOFREMIP/CRI/IMIDIATE consortium and contributors*

**Letters**

**539** Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area

*R Bourguiba, M Delplanque, C Vinit, F Ackermann, L Savey, G Grateau, V Hentgen, S Georin-lavialle*

**540** Do autoantibody-responses mature between presentation with arthralgia suspicious for progression to rheumatoid arthritis and development of clinically apparent inflammatory arthritis? A longitudinal serological study

*F Wouters, E Niemantsverdriet, N Salioska, A L Dorjée, R E M Toes, A H M van der Helm-van Mil*

**542** Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation

*T Mori, M Saburi, M Hagihara, M Mori, R Yamazaki, J Kato*

**543** Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis



*Y Ding, B Huang, Y Wang, J Hou, Y Chi, Z Zhou, J Li*

**545** Impact of grouping serial journal articles by disease category: analysis of article placement order in ARD 2013–2019

*J Hill, N Dalbeth, G D Gamble, A Grey, S Stewart*

**Electronic pages**

**e46** Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort

*L Costa, M Tasso, N Scotti, E Mostacciolo, L Girolimetto, F Foglia, A del Puente, R Scarpa, F Caso*

**e47** Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa *et al*

*L Gupta, D P Misra, V Agarwal, S Balan, V Agarwal*

**e48** Telemedicine will not keep us apart in COVID-19 pandemic

*S Perniola, S Alivernini, V Varriano, A Paglionico, G Tanti, P Rubortone, L Lanzo, F Melpignano, C Tur, E De Lorenzis, G Peluso, A Capacci, E Gremese*

**e49** Response to: 'Telemedicine will not keep us apart in the COVID-19 pandemic' by Perniola *et al*

*E Bozzalla Cassione, G Zanframundo, A Biglia, V Codullo, C Montecucco, L Cavagna*

**e50** COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases

*C López-Medina, A Escudero, E Collantes-Estevez*

**e51** Response to: 'COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases' by Lopez-Medina *et al*

*E Bozzalla Cassione, G Zanframundo, A Biglia, V Codullo, C Montecucco, L Cavagna*

**e52** Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey

*M Plüß, G Chehab, P Korsten*

**e53** Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß *et al*

*A Mathian, Z Amoura*

**e54** Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

*L Carbillon, A Benbara, J Boujenah*

- e55** Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon *et al*  
*M F Konig, M Gianfrancesco, J Yazdany, P C Robinson*
- e56** Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak  
*J Holubar, M Le Quintrec, H Letaief, J L Faillie, Y-M Pers, C Jorgensen*
- e57** Response to: 'Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak' by Holubar *et al*  
*A Mathian, Z Amoura*
- e58** Case series of acute arthritis during COVID-19 admission  
*M-C López-González, M L Peral-Garrido, I Calabuig, E Tovar-Sugrañes, V Jovani, P Bernabeu, R García-Sevila, J-M León-Ramírez, O Moreno-Perez, V Boix, J Gil, E Merino, P Vela, M Andrés*
- e59** Response to: 'Case series of acute arthritis in COVID-19 admission' by López-González *et al*  
*E R Graef, J W Liew, A HJ Kim, J A Sparks*
- e60** Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic  
*G E Fragoulis, G Evangelatos, A Arida, V-K Bournia, K Fragiadaki, A Karamanakos, E Kravvariiti, K Laskari, S Panopoulos, M Pappa, M C Tektonidou, P P Sfikakis*
- e61** Response to: 'Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic' by Fragoulis *et al*  
*H Schulze-Koops, K Krueger, C Specker*